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Ion channel ligand bindingIntegral membrane proteins (IMPs) are of therapeutic interest and are targeted by a majority of approved drugs.
It's difﬁcult to express, purify, and maintain the functional conformation of IMPs. Nanodisc presents a reliable
method to solubilize and stabilize IMPs in detergent-free condition. In this study, we demonstrate the assembly
and puriﬁcation of a chimeric ion channel, KcsA-Kv1.3 Nanodisc. We further detail biophysical analysis of the
assembled Nanodisc using analytical ultracentrifugation (AUC), surface plasmon resonance (SPR), and back
scattering interferometry (BSI). AUC is employed to determine the molecular composition of the empty and
KcsA-Kv1.3Nanodisc. Combination of SPR andBSI overcomes each other's limitation andprovides insight of equi-
librium binding properties of peptide and small molecule ligands to KcsA-Kv1.3.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
IMPs are important therapeutic targets of more than 50% of
approved drugs [1–3], and they can be classiﬁed into different groups
according to their structure and function. Different classes of IMPs all
heavily rely on insertion in the lipid bilayer of cellular membranes to
maintain active conformations and/or exert function. The biochemical
and biophysical properties of IMPs are typically not fully characterized
due to the challenges of preserving native conformations during
puriﬁcation. Even though more and more IMPs have been puriﬁed and
crystallized [4,5], high concentrations of detergents that are required
to maintain their solubility in aqueous solutions often interfere with
characterization methods. Over the years, different methods have
been developed to study IMPs by incorporating them into bicelles,
micelles and liposomes [6–10]. For instance, binding of toxin ligands
to KcsA has been studied extensively using radio-labeled ligands and
detergent solubilized KcsA [11–13]. While bicelles, micelles, and
liposomes are still serving the fundamental needs of characterization
of binding and functional properties of IMPs, methods of mimicking
the lipid bilayer using synthetic polymers, such as polymersome [14]R, G-protein coupled receptor;
o-3-phosphocholine; IMP, inte-
BSI, back scattering interferom-
ucleotide binding domain; SV,and amphiphile [15,16], also present the potential of incorporating or
encapsulating the IMPs. However, these methods usually only allow
restricted access of either the cytosolic or the extracellular side of any
single target protein for binding studies. In addition, mixed orientations
among the population of target proteins may impede quantitative
characterization. Although the recently reported spontaneous reconsti-
tution of native Nanodisc [17] can provide a facile puriﬁcation method
of membrane protein with good stability, the intrinsic heterogeneity
presents challenges to detailed biochemical and biophysical characteri-
zation of the IMPs. Nanodiscs [18,19] from directed assembly embed
target protein in a lipid bilayer, which is further stabilized by a pair of
membrane scaffold proteins (MSP) in antiparallel fashion. This type of
constructs is a great complimentary of existing methods, and has
the advantages of 1) stabilizing a variety of IMPs in their native confor-
mation in a detergent-free environment, 2) presenting accessibility of
both intra- and extra-cellular domains of the target IMP to ligand/
effector proteins, and 3) generating a solution with homogenous parti-
cle size. Although many different types of IMPs have been successfully
incorporated in Nanodiscs, examples of the assembly of ion channel
Nanodiscs are limited [20,21]. Recent study on KcsA/MloK1 [21]
demonstrated beneﬁt of using Nanodisc to determine ligand binding
to grafted cyclic nucleotide binding domain (CNBD) from MloK1
onto KcsA in a detergent free environment. However, details of
conformation and inhibitor binding properties in the pore region of
the potassium channel remained unclear.
Voltage gated potassium channel Kv1.3 plays a critical role in
regulating T-lymphocyte proliferation and activation [22,23]. Kv1.3
1975H. Xu et al. / Biochimica et Biophysica Acta 1848 (2015) 1974–1980belongs to the Shaker-related family of potassiumchannels that consists
of a homo-tetramer with six transmembrane helices (S1–S6) from each
monomer [24]. Helices S1–S4 are responsible for voltage sensing. S5, S6
and the P-loop region between S5 and S6 from eachmonomer form the
pore domain that is selective for K+. The pore domain also conducts
channel gating. The Stichodactyla toxin (ShK) has been demonstrated
to exert an anti-inﬂammatory effect through blocking Kv1.3 [13,25,
26]. PEG-ShK, a derivative of ShK, shows a similar Kv1.3 inhibitory effect
with higher speciﬁcity and longer in vivo half-life [27]. Further drug
discovery efforts also identiﬁed small molecules that can block Kv1.3
current [28], such as PAP-1 [29]. Our internal drug discovery effort has
identiﬁed Compound 1 [30] with blocking activity of Kv1.3 current.
Although the functional activity of these compounds has been well
studied, only limited information is available of ShK binding to Kv1.3Fig. 1. Summary of KcsA-Kv1.3 Nanodisc assembly and analytical characterization. A. Alignment
shaded, and residues from the S5–S6 domain of Kv1.3 grafted on to KcsA are underlined. B. Sch
Nanodisc) or KcsA-Kv1.3 (tetramer), MSP, and lipid weremixed at 1:8:320 molar ratio (KcsA-K
using XAD BioBeads to form Nanodisc. At last, KcsA-Kv1.3 Nanodisc was puriﬁed from excess
empty Nanodisc (Empty Nd), KcsA-Kv1.3 Nanodisc (K-K Nd), and detergent solubilized KcsA
Kv1.3 are present in the detergent solubilized material even under denaturing condition, indica
served in KcsA-Kv1.3 Nanodisc with the presence of dimer, but the content of tetramer is sign
diameters of assembled Nanodiscs by HPLC analysis. The column is calibrated using standards w
eter to generate the standard curve. The diameters of empty and KcsA-Kv1.3 Nanodiscs were c
column ♦: standards;●: empty Nanodisc; ■: KcsA-Kv1.3 Nanodisc.micelles through radio-active binding assay [13]. Binding properties of
PEG-ShK, PAP-1, and Compound 1 have not been determined.
While the structure of Kv1.3 remains unresolved, theX-ray structure
of bacterial potassium channel, KcsA, has been resolved to 3.2 Å [31].
KcsA consists of a homo-tetramer with two transmembrane helices
from each monomer. The loop region between the two helices forms
the K+ pore. The pore region is highly conserved between eukaryotic
and prokaryotic species [11]. In this article, we constructed chimeric
KcsA-Kv1.3 [12] potassium channel in Nanodisc by grafting selected
residues of the pore region of Kv1.3 onto KcsA (Fig. 1A). Our study
demonstrated that Kv1.3 inhibitors can recognize the pore region of
Kv1.3 on KcsA scaffold. We determined stoichiometry of the molecular
components of KcsA-Kv1.3 Nanodisc using the analytical ultracentrifu-
gation (AUC)method. Determination of direct ligand binding propertiesof theM1/M2 domain fromKcsA and the S5/S6 domain of Kv1.3.Mismatched residues are
eme of Nanodisc assembly. Brieﬂy, MSP and lipid were mixed at 1:80 molar ratio (empty
v1.3 Nanodisc) in sodium cholate containing solution. Then sodium cholate was removed
empty Nanodisc using Ni-NTA column. C. 4–20% tris–glycine reducing SDS-PAGE of MSP,
-Kv1.3 (det. sol. K-K). Monomer (K-K M), dimer (K-K D), and tetramer (K-K T) of KcsA-
ting an incomplete denaturing state of the protein. Incomplete denaturation was also ob-
iﬁcantly reduced comparing to detergent solubilized KcsA-Kv1.3 D. Calculation of Stokes
ith different Stokes diameters. E. The respective retention times plotted against the diam-
alculated to be 9.5 and 11 nm, respectively, according to their retention time on the same
1976 H. Xu et al. / Biochimica et Biophysica Acta 1848 (2015) 1974–1980of membrane proteins remains a challenge. Binding methods, such as
SPR and NMR, that measure direct ligand-IMP interactions are often
hampered by limited detection sensitivity and thus, not sufﬁcient if
used alone. In addition, conventional radio ligand binding methods
that employ crude membrane preparations can only detect binding at
sites either competitive to or allosterically coupled with the tracer.
We overcame these hurdles and obtained detailed direct binding
information of peptide and small molecule ligands of Kv1.3 through
combination of SPR and BSI methods.
In summary, our studies demonstrate that determination of direct
ligand-channel interaction is achievable using a combination of the
Nanodisc technology and sensitive detection methods. Details of ligand
binding properties of Kv1.3 can help to articulate the differences in their
functional activity and facilitate the design of Kv1.3 inhibitors with
more favorable pharmacokinetic and pharmacodynamics properties.
2. Methods
2.1. Protein expression and puriﬁcation
MSP1D1-D73C28 was licensed from Dr. Stephen Sligar's lab at
University of Illinois at Urbana-Champaign, and was expressed and
puriﬁed as described previously [32,33]. Puriﬁed and histidine tag-
cleaved MSP were biotinylated using the EZ Link Iodoacetyl-PEG2-Bio-
tin kit (Thermo Scientiﬁc) according to the instructions. Complete
biotinylation was conﬁrmed by mass spectrometer analysis (data not
shown). MSPs were conjugated with an Alexa Fluor® 488 using C5-
maleimide kit (Life Technologies) according to manufacturer's instruc-
tions, and the degree of labelingwas determined by spectrophotometric
methods.
Chimeric KcsA-Kv1.3 was expressed with an N-terminal His6 tag in
Escherichia coli as previously described [12]. Cells were lysed in a buffer
of 20mMTris–HCl, 5mM imidazole, 150mMKCl, pH 7.5, and Complete
Protease Inhibitor cocktail (Roche). Unbroken cells and inclusion
bodies were removed by centrifugation (20,000 g, 1 h, 4 °C), andmem-
branes were collected from the supernatant by ultracentrifugation
(100,000 g, 1 h, 4 °C). Membranes were solubilized in lysis buffer
containing 40 mM DDM and clariﬁed by ultracentrifugation. KcsA-
Kv1.3 was puriﬁed from the supernatant using Talon afﬁnity
resin (Clontech) equilibrated with lysis buffer containing 5 mM
dodecylmaltoside (DDM) and eluted with the same buffer containing
100 mM imidazole. Fractions containing KcsA-Kv1.3 chimera were
pooled and further puriﬁed on a Superdex 200 column (GE Healthcare).
2.2. Nanodisc assembly
To assemble empty Nanodiscs, biotin-MSP-1D1-D73C and 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC, Avanti Lipids) were
mixed at 1:80 molar ratio in the presence of 14 mM sodium cholate in
the Nanodisc assembly buffer containing 100 mM NaCl, 20 mM Tris–
HCl, pH 7.5, and 0.5 mM EDTA. To assemble the KcsA-Kv1.3 containing
Nanodisc, KcsA-Kv1.3 (tetramer), biotin-MSP1D1-D73C, and DMPC
were mixed at 1:8:320 molar ratio in the presence of 14 mM sodium
cholate in the assembly buffer. The mixtures were incubated at room
temperature (~25 °C) for 1 h before sodium cholate was removed
using XAD-2 bio-beads (Sigma). After detergent removal, KcsA-Kv1.3
containing Nanodisc was separated from the excess empty Nanodisc
by Ni-NTA resin (Pierce). The component proteins of the Nanodiscs
were visualized on a 4–20% SDS-PAGE. The Stokes diameters were
determined on an HPLC system (Beckman System Gold) equipped
with a Superdex-200 10/300 GL gel ﬁltration column (GE Healthcare).
Nanodisc buffer was used as the mobile phase with a ﬂow rate at
0.6 ml/min. The wavelength of the UV detector was set at 280 nm.
Protein standards with respective Stokes diameter were used for size
calibration as follows: thyroglobulin (17 nm); bovine liver catalase
(10 nm) and bovine serum albumin (7 nm). The retention time ofstandards was plotted against the diameter to generate the standard
curve. Diameters of Nanodiscs were determined using the standard
curve corresponding to their retention time.
2.3. AUC analysis
Sedimentation velocity (SV) AUC experiments were conductedwith
Nanodiscs containing Alexa 488 labeled MSP, using a Beckman Coulter
ProteomeLab XL-I analytical ultracentrifuge. Data were collected at
40,000 rpm and at 20.0 °C using the absorbance optical system for
both 280 nm and 496 nm detections, and the interference optical
system, as well as in a separate experiment, using the ﬂuorescence
detection system (FDS) (ex. 496 nm, em. 519 nm) (Aviv Biomedical,
Lakewood, NJ). SV cells were assembled from 12 mm Spin60™
double-sector, charcoal epon centerpieces and sapphire windows
obtained from Spin Analytical, Inc. (Berwick, Maine). The raw data SV
scans were analyzed using the c(s) method in the software program
SEDFIT (v14.4d) by Peter Schuck [34]. A conventional c(s) distribution
was ﬁt to the meniscus position as well as the time independent
noise, with a ﬁxed regularization conﬁdence level of 0.68. A single
frictional ratio (f/f0) obtained with the 280 nm detection data, was
used as a ﬁxed parameter in the analyses of the data for the other detec-
tion methods.
Since everymolecule comprising a givenNanodisc contributes to the
interference signal, the peak area, from the corresponding sedimenta-
tion coefﬁcient spectrum, could be correlated to the amount of every
type of component comprising a Nanodisc. This was accomplished
through correlating the peak area to the interference molar signal
increment for a Nanodisc (εJ-Nd), which corresponds to the sum of
the molar signal increment for each type of component weighted by
the respective stoichiometries of the components, according to the
following equation [19].
ε J Nd ¼ nε J MSPþ xε J KKþ yε J DMPC ð1Þ
where the coefﬁcients n, x, and y correspond to the stoichiometries of
the respective components, MSP, KcsA-Kv1.3 protein, and DMPC
(note, for the empty Nanodisc, x = 0). εJ_MSP, εJ_KK, and εJ_DMPC
correspond to the interference molar signal increments for the MSP,
KcsA-Kv1.3 protein, and DMPC lipid components respectively, which
were determined from their respective molecular weight (MW) and
refractive index increment (dn/dc) as follows:
ε J ¼ MW=1000ð Þ dn=dcð Þ=675:0E7: ð2Þ
The respective dn/dc values for the protein components were
determined from their amino acid compositions using the calculator
function in SEDFIT v14d, giving values: MSP: 0.1842, KcsA-Kv1.3:
0.1866. A dn/dc value for DMPC of 0.1398 was obtained as described
in Winzen et al [35].
The stoichiometry value for the KcsA-Kv1.3 protein portion of the
assembled Nanodisc, was then determined from the best ﬁt of the
280 nm and interference data. The lipid stoichiometries for both types
of Nanodiscs were determined from the interference results. The
496 nm detection results were used to calibrate the amount of MSP
per Nanodisc, given an extinction coefﬁcient for Alexa 488 at 496 nm
(~71,000 M−1 cm−1), which equaled a value of 2 per Nanodisc, and
therefore, in Eq. (1), n= 2.
In a similar manner, the molecular weights and partial speciﬁc
volumes of the Nanodiscs were calculated from the respectiveweighted
contributions of each component, based on the stoichiometries of
assembly determined from the extinction coefﬁcients and integrated
peaks areas.
Fig. 2. Results from SV analyses of empty Nanodiscs (A) and KcsA-Kv1.3 Nanodiscs
(B)monitoredwith the absorbance optical system(280 nmand 496 nm), and interference
optical system, plotted as c(s), sedimentation coefﬁcient distribution spectra. The major
peaks from all three optical detections superimpose. The major sedimenting species,
determined from the 280 nm scans for the empty Nanodiscs and the KcsA-Kv1.3
Nanodiscs, have values of 3.0 S and 5.2 S, respectively.
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SPR studies were performed on a Biacore T200™ instrument
(GE Healthcare) at 25 °C. Biotinylated Nanodiscs with or without
KcsA-Kv1.3 were captured onto a regenerable streptavidin sensorchips
(CAP chip, GE Healthcare), and the surface was regenerated with a
mixture of guanidine HCl and NaOH per kit instructions. Using the
single-cycle kinetics method, serially diluted ligands, including ShK
peptide (Alomone) and PEG-ShK, were injected sequentially over
Nanodisc surfaces for 2 minute association followed by 30 minute
dissociation at a ﬂow rate of 70 μl/min. To obtain binding constants,
the raw data was ﬁt to a 1:1 binding model including a mass transfer
limitation term using Biacore Evaluation software (GE Healthcare).
2.5. BSI analysis
KcsA-Kv1.3 and empty Nanodiscs were diluted in binding buffer to
0.6–1.2 nM. Small molecule ligands, ShK, PEG-ShK peptides were
serially diluted in the binding buffer and mixed with equal volume of
Nanodisc for BSI measurement. Peptide/Nanodisc mixture was incubat-
ed at room temperature, and small molecule/Nanodisc mixture was in-
cubated at 30 °C for 2 h before the binding signal wasmeasured using a
pre-commercial prototype device (Molecular Sensing Inc., Nashville,
TN). The temperature during the measurement was controlled at
25 °C and 28 °C for peptide and small molecule ligand, respectively,
with a precision of +/−0.001 °C. Binding signals were expressed as
phase shift of obtained interference fringe patterns as measured in mil-
liradians. Binding to empty Nanodisc was used to subtract background
binding. The equilibrium constant (Kd) was derived from non-linear
least-squares ﬁtting of the data using the one-site saturation binding
model.
2.6. Electrophysiology characterization
Human Kv1.3 channel was recombinantly expressed in CHO cells.
Inhibitory activities of the compounds on Kv1.3 were determined by
monitoring Kv1.3 current with and without compound treatment on
PatchXpress 7000A (Molecular Devices) at 25 °C. The holding potential
was at−80mV. The testing potential was at 30mV. The pulse duration
was 20 ms.
3. Results
3.1. Nanodisc assembly
We constructed the chimeric potassium channel, KcsA-Kv1.3, for
Nanodisc assembly to take advantage of the feasibility of expression
and puriﬁcation of KcsA and therapeutic interest of Kv1.3. We grafted
selected residues of the pore region of the S5–S6 domain of human
Kv1.3 channel onto theM1–M2 region of KcsA to enable binding of ther-
apeutic inhibitors of Kv1.3 [27,29] to the KcsA-Kv1.3 chimeric protein
(Fig. 1A). MSP-1D1 with single cysteine mutation at residue 73 and
DMPC were selected for Nanodisc assembly. The cysteine residue was
employed in order to enable site-speciﬁc biotinylation and ﬂuorophore
labeling of the MSP-1D1. The site speciﬁc biotinylation on Nanodiscs
provided a stable attachment in a relatively uniform orientation of the
Nanodiscs to the biosensor SPR chip surface, and the site speciﬁc
attachment of the ﬂuorescent dye enabled a quantitative assessment
of the assembly properties by the AUC analysis. After assembly, the
KcsA-Kv1.3 Nanodiscs were puriﬁed from the excess empty Nanodiscs
and aggregates by Ni-NTA afﬁnity chromatography (Fig. 1B). The
protein composition of the assembled Nanodiscs was conﬁrmed by
SDS-PAGE (Fig. 1C). Bands corresponding to MSP and KcsA-Kv1.3
were observed as expected for KcsA-Kv1.3 Nanodisc. Worth noting
that bands corresponding to the molecular weight of monomer,
dimer, and tetramer of KcsA-Kv1.3 were observed in the detergentsolubilized KcsA-Kv1.3 sample even under denaturing and reducing
conditions, indicating a stable oligomer formation. Dimer andmonomer
bands were observed for Nanodisc under the same condition. The
monodisperse state (Fig. 1D) and Stokes diameters of the assembled
KcsA-Kv1.3 and empty Nanodiscs were determined by size exclusion
chromatographyusing a Beckman SystemGoldHPLC (BeckmanCoulter,
CA) to be 11.0 nm and 9.5 nm, respectively (Fig. 1E).
3.2. AUC to determine molecular composition in Nanodisc
The AUC method of SV analysis [19] was used to determine the
protein-to-lipid ratio and molecular composition for KcsA-Kv1.3 and
empty Nanodiscs assembled with Alexa Fluor® 488-labeled MSP. Data
were collected using both the absorbance optical system (with readings
at 280 nm and 496 nm) and the interference optical system, and in a
separate experiment, with the ﬂuorescence detection system (FDS).
Results from the interference and two absorbance signals were
analyzed by c(s) analysis in SEDFIT v14d to generate sedimentation
velocity spectra. The major peaks from all three measurements were
superimposed, and sedimentation coefﬁcients determined for Alexa
Fluor® 488-KcsA-Kv1.3 Nanodiscs and the empty Nanodiscs from the
major peaks were 5.2S and 3.05S (Fig. 2 and Table 1), respectively.
Table 1
Sedimentation coefﬁcients of the Nanodiscs and molecular numbers of the components in each Nanodisc determined by AUC.
Sample Sed. coef. (S) MW (kDa) Frictional ratio (f/f0) Partial speciﬁc volume (ml/g) Stoichiometry in Nanodisc
MSP1D1 D73C KcsA/Kv1.3 DMPC
Alexa488_KK_Nd 5.2 203 1.52 0.81 2 4 114
Alexa488_empty_Nd 3.1 147 1.43 0.87 2 0 144
1978 H. Xu et al. / Biochimica et Biophysica Acta 1848 (2015) 1974–1980Assuming each Nanodisc contains two copies of MSP, the main peaks
from all three measurements in this study are composed of 144 DMPC
molecules for the empty Nanodiscs and 114 DMPC and four KcsA-
Kv1.3 monomers for the KcsA-Kv1.3 Nanodiscs. These results are
consistent with the established Nanodisc models [18] and expected
stoichiometry of KcsA [31].
SV studies revealed minor components in addition to KcsA-Kv1.3
Nanodiscs and empty Nanodiscs. Although the exact composition of
the minor molecular species will have to be determined by more
detailed global analysis, such as through incorporating equilibrium
sedimentation studies, a few minor peaks, present only with the inter-
ference detection but not the UV or visible detection (Figs. 2A and B),
nor the ﬂuorescence detection (data not shown), are likely to beFig. 3. Analysis of peptide and small molecule inhibitors binding to KcsA-Kv1.3 Nanodisc. A.
Biacore™ T-200. Binding equilibrium constants of ShK or PEG-ShK3 toKcsA-Kv1.3Nanodiscwer
in buffer consisting of 20mMTris pH 7.5, 100mMNaCl, 0.5mMEDTA, and 0.01% BSA. Signal diff
the gray lines and theﬁtted curves are represented by the black lines. The association and dissoc
in this plot for all but the last injection in order to show the association phase properly. B. Respe
constants of Kv1.3 channel blocking peptides, ShK and PEG-ShK, on KcsA-Kv1.3 Nanodisc were
0.01% BSA. Empty Nanodisc was used as negative control withminimumbinding to ShK (shown
molecule inhibitors on KcsA-Kv1.3 Nanodiscs were determined under similar conditions usingDMPC micelles in different sizes. In addition, there is a 496 nm absor-
bance peak at 2S for the KcsA-Kv1.3 Nanodisc without UV absorbance
at 280 nm (Fig. 2B), and we interpret this as trace amount of free
Alexa Fluor® 488 carried over from the MSP labeling procedure,
which is corroborated by the ﬂuorescence results (data not shown).
3.3. Peptide ligand binding study by SPR
Peptide ligand binding equilibrium constants (Kd) of KcsA-Kv1.3
Nanodisc were determined using SPR spectroscopy on a Biacore™
T200. KcsA-Kv1.3 or empty Nanodisc was immobilized through biotin-
streptavidin interaction on the sensorchip. ShK or PEG-ShK solutions
with escalating concentration were injected over the Nanodisc surfaceBinding constants of peptide inhibitors to KcsA-Kv1.3 Nanodisc were determined using
e determined by sequential injection of serially dilutedpeptides over theNanodisc surfaces
erences between KcsA-Kv1.3 and emptyNanodisc surfaces (background) are presented by
iation periodswere 2min and 30min, respectively. Thedissociation phaseswere truncated
ctive skeletal structures for the two small molecules analyzed in D. C. Binding equilibrium
determined by BSI in buffer containing 20mM Tris, pH 7.5, 100mMNaCl, 5 mM EDTA, and
inﬁgure) and PEG-ShK (data not shown). D. Binding equilibrium constants of Kv1.3 small
BSI. Minimum binding of both compounds was observed on empty Nanodisc.
1979H. Xu et al. / Biochimica et Biophysica Acta 1848 (2015) 1974–1980sequentially. Minimum binding was observed for both peptides on
emptyNanodisc surface, and the signalwas subtracted from the binding
signals on KcsA-Kv1.3 surface (Fig. 3A). Dose dependent binding was
observed for ShK and PEG-ShK with equilibrium constants at 51 pM
and 27 pM, respectively (Table 2). The binding afﬁnity of ShK is very
similar to its activity of blocking Kv1.3 current (39 pM). It was also
within two-fold of the previously determined value in a competitive
membrane binding assay using radio-labeled ligand (125I-ChTX) [13].
However, the binding afﬁnity of PEG-ShK is ~50 fold higher than its
blocking activity (1.5 nM). The maximum binding of ShK and PEG-ShK
(13 RU and 16 RU, respectively) to the KcsA-Kv1.3 surface in SPR was
similar to the theoretical values (14 RU and 20 RU, respectively),
indicating that the majority of the chimeric proteins assembled in
Nanodiscs are in the ligand-recognizing conformation. In addition, the
pore region of Kv1.3 preserved its ligand binding activity after grafted
onto KcsA.We also attempted to determineKd for PAP-1 andCompound
1 on Biacore™ T200, but the binding of small molecule ligandswere be-
yond the detection limits of Biacore™ T200.
3.4. Peptide and small molecule ligand binding by BSI
BSI is a more suited detection method than SPR for small molecule
binding to a large receptor as the binding signal is not molecular weight
dependent, but sensitive to conformational changes in protein [36].
Since we were not able to obtain reliable results of PAP-1 or Compound
1 binding to KcsA-Kv1.3 Nanodisc by SPR, BSI was employed as a
complimenting method to determine Kd of the small molecule ligands.
PAP-1 or Compound 1 in dose dilution was mixed with 600 pM KcsA-
Kv1.3 or empty Nanodisc and incubated at 30 °C for 2 h before binding
signal was measured. Dose dependent signal was observed for both
compounds when mixed with KcsA-Kv1.3 Nanodisc, while minimum
binding signal was observed when mixed with empty Nanodisc
(Fig. 3C). Binding constants for these small molecule ligands (3.1 nM
for PAP-1 and 29.8 nM for Compound 1) were consistent with their ac-
tivities (9.72 nM for PAP-1 and 91.3 nM for Compound 1) on blocking
Kv1.3 current (Table 2). Kd of peptide ligands were also determined in
BSI study (Fig. 3c). ShK or PEG-SHK were incubated with 300 pM
KcsA-Kv1.3 or emptyNanodisc at room temperature for 2 h before bind-
ing signal was measured. Binding constants of ShK (200 pM) and PEG-
ShK (100 pM) were signiﬁcantly higher than the values determined
by SPR. For ShK, the binding afﬁnity was ~ﬁve folder weaker than the
activity on cell assay (39 pM). For PEG-ShK, both SPR and BSI showed
signiﬁcantly higher binding afﬁnity than the cellular activity (1.5 nM).
4. Discussion
In this study, we have successfully demonstrated that an ion
channel, KcsA-Kv1.3, can be assembled into a Nanodisc and retain its
ligand recognizing conformation in a detergent free solution. We have
demonstrated that assembledNanodiscs showuniform size distribution
with target protein: MSP: lipid, or MSP:lipid molar ratio consistent with
previous publications. We have determined binding Kd of peptide and
small molecule ligands to KcsA-Kv1.3 using combination of SPR andTable 2
Summary of binding and functional activities of peptide and small molecule ligands on
KcsA-Kv1.3.
Ligand Kda (nM)
BSI
Kda (nM)
SPR
IC50b (nM)
Ephys
ShK 0.20 ± 0.04 0.051 ± 0.014 0.039 ± 0.023
PEG-ShK 0.10 ± 0.02 0.027 ± 0.003 1.50 ± 0.80
PAP-1 3.1 ± 0.6 NDc 9.72 ± 3.3
Compound 1 29.8 ± 4.5 NDc 91.3 ± 18.8
a Determined on KcsA-Kv1.3 Nanodisc.
b Determined on Kv1.3 recombinant cell line.
c Not determined.BSI technologies. The PEG-ShK showed higher binding afﬁnity by SPR
and BSI than its inhibitory function of the Kv1.3 ion channel in the
cellular assay. Since PEG-ShK was the only compound that displayed
inconsistency between binding and functional potency, mis-folding of
the KcsA-Kv1.3 in Nanodiscs was not likely the contributing cause. The
physical properties of the pegylated peptide (e.g. hydrophobicity,
viscosity and diffusion rate) may reduce its apparent inhibitory cellular
activity compared to its binding afﬁnity determined using puriﬁed
protein reconstituted in a Nanodisc.
We have also noticed that the small molecule binding required a
higher temperature (30 °C) than peptide binding (~25 °C). This could
indicate that these two classes of ligands bind to different sites of
KcsA-Kv1.3. The binding site(s) for the small molecules may require
higher mobility of the lipids surrounding KcsA-Kv1.3, therefore, only
bind at temperature signiﬁcantly higher than the phase transition
temperature of DMPC (24 °C).
Signiﬁcant discrepancy between the Kd values determined by SPR
and BSI of peptide ligands was observed. Although the SPR and BSI
studies both showed sub-nanomolar interaction between KcsA-Kv1.3
and its peptide inhibitors, the afﬁnities for both peptides appeared to
be 4–5 fold weaker by BSI than the values determined by SPR. The
requirement of 300 pM of Nanodiscs to generate reliable and robust
signals in BSI is above the expected Kd values for both peptides, such
that the binding events are occurring in stoichiometric binding space
where assessment of equilibrium constants are not reliable [37]. Deter-
mination of small molecule binding to KcsA-Kv1.3 Nanodiscs was not
feasible by SPR since the molecular weight change upon binding
appeared beyond the detection limit. Therefore, BSI was a more favor-
able option to determine the interactions of small molecule inhibitors
with KcsA-Kv1.3 Nanodiscs. In conclusion, the combination of SPR and
BSI technologies effectively determined binding properties of both
peptide and small molecule inhibitors to KcsA-Kv1.3 Nanodisc. In
addition, consistency between binding afﬁnity of these inhibitors and
their functional results further demonstrated correct folding of the
chimeric ion channel in the Nanodiscs. We have been able to reproduce
the assembly of the KcsA-Kv1.3 Nanodisc multiple times, and subse-
quently demonstrate itsmonodisperse state and ligand binding activity.
We have also applied Nanodisc technology on different classes of mem-
brane proteins and obtained similar results. Our experience with the
reproducibility of Nanodisc assembly and characterization, along with
numerous other publications on Nanodisc, demonstrated it can be a
facile and viable alternative to traditional membrane protein methods,
such as micelle, bicelle, and liposomes.5. Conclusion
We have demonstrated that an integral membrane ion channel can
be incorporated into Nanodiscs and retain its ligand recognizing
functional conformation. This approach, in combination with SPR and
BSI, has enabled detailed small molecule and peptide inhibitor — ion
channel interaction studies, which to this date have been largely intrac-
table. Furthermore, SPR and BSI methods are compatible with formats
for medium to high throughput assays, suggesting a strong applicability
of the Nanodisc platform for ion channel drug discovery.Authors' contribution
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